40 results found.

Plaque Psoriasis Clinical Trial using MK-3222 200 mg; MK-3222 100 mg; Matching Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010).
MK-3222 200 mg; MK-3222 100 mg; Matching Placebo

Plaque Psoriasis Clinical Trial using MK-3222 200 mg; MK-3222 100 mg; MK-3222 Placebo; Etanercept Placebo; Etanercept 50 mg

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 9000222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis.
MK-3222 200 mg; MK-3222 100 mg; MK-3222 Placebo; Etanercept Placebo; Etanercept 50 mg

Psoriasis Clinical Trial using Adalimumab (Humirar); ABP 501

Amgen - Recruiting 18 years to 75 years.
- A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of ABP 501 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis.
Adalimumab (Humirar); ABP 501

Psoriasis Clinical Trial using BI 655066; Ustekinumab

Boehringer Ingelheim - Recruiting 18 years to 75 years.
- A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066).
BI 655066; Ustekinumab

Chronic Plaque-type Psoriasis Clinical Trial using CJM112; Secukinumab; Placebo

Novartis - Recruiting 18 years to 65 years.
- A Randomized, Double-blind, Placebo and Positive Controlled, Single and Multiple Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJM112 in Chronic Plaque-type Psoriasis Patients.
CJM112; Secukinumab; Placebo

Moderate to Severe Plaque-type Psoriasis Clinical Trial using Secukinumab (AIN457); Placebo

Novartis - Recruiting 18 years or older.
- A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long-term Efficacy, Safety, and Tolerability up to 2 Years in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab.
Secukinumab (AIN457); Placebo

Moderate to Severe Palmoplantar Psoriasis Clinical Trial using secukinumab 150 mg; secukinumab 300 mg; Placebo

Novartis - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 80 Weeks in Subjects With Moderate to Severe Palmoplantar Psoriasis.
secukinumab 150 mg; secukinumab 300 mg; Placebo

Psoriasis Clinical Trial using Ustekinumab; Abatacept; Placebo for Ustekinumab; Placebo for Abatecept

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 65 years.
- Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI).
Ustekinumab; Abatacept; Placebo for Ustekinumab; Placebo for Abatecept

Plaque Psoriasis Clinical Trial using DFD01 Spray; Comp01 Lotion

Promius Pharma, LLC - Recruiting 18 years to 90 years.
- .
DFD01 Spray; Comp01 Lotion

Psoriasis Clinical Trial using etanercept

Amgen - Recruiting 18 years or older.
- Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab.
etanercept

Psoriasis Vulgaris, or Psoriasis Clinical Trial using tofacitinib ointment 20 mg/g; tofacitinib ointment 10 mg/g; placebo ointment (vehicle)

Pfizer - Recruiting 18 years or older.
- A Phase 2b, Multi-Site, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Of The Efficacy, Safety, Local Tolerability And Pharmacokinetics Of 2 Dose Strengths And 2 Regimens Of Tofacitinib Ointment In Subjects With Chronic Plaque Psoriasis.
tofacitinib ointment 20 mg/g; tofacitinib ointment 10 mg/g; placebo ointment (vehicle)

Psoriasis Clinical Trial using CP-690,550

Pfizer - Recruiting 18 years or older.
- A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis.
CP-690,550

Psoriasis Clinical Trial

Rockefeller University - Recruiting 18 years to 75 years.
- Psoriasis Inflammation and Systemic Co-Morbidities: Is it Preventable or Reversible?.

Psoriasis Clinical Trial

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- French Multicentric Prospective Observational Cohort of Patients Receiving Systemic Treatment for Psoriasis.

Psoriasis Vulgaris Clinical Trial using Calcipotriol/betamethasone dipropionate gel

Samsung Medical Center - Recruiting 19 years or older.
- Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris.
Calcipotriol/betamethasone dipropionate gel

Psoriasis Clinical Trial using DFD01 Spray; Vehicle Spray

Promius Pharma, LLC - Recruiting 18 years or older.
- .
DFD01 Spray; Vehicle Spray

Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Eryt Clinical Trial using Interleukin 2

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach.
Interleukin 2

Psoriasis Clinical Trial using DFD01 Spray; Comp01 Lotion; Vehicle Lotion; Vehicle Spray

Promius Pharma, LLC - Recruiting 18 years or older.
- .
DFD01 Spray; Comp01 Lotion; Vehicle Lotion; Vehicle Spray

Psoriasis Clinical Trial using ASKP1240; Placebo

Astellas Pharma Inc - Recruiting 18 years to 75 years.
- A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis.
ASKP1240; Placebo

Plaque Type Psoriasis Clinical Trial using GP2017 Adalimumab; Humira r Adalimumab

Sandoz - Recruiting 18 years or older.
- A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humirar in Patients With Moderate to Severe Chronic Plaque-type Psoriasis.
GP2017 Adalimumab; Humira r Adalimumab

Psoriasis Clinical Trial using 80 mg ixekizumab; 50 mg etanercept; Placebo

Eli Lilly and Company - Recruiting 18 years or older.
- A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period.
80 mg ixekizumab; 50 mg etanercept; Placebo

Psoriasis, Arthritic Clinical Trial using ixekizumab; Placebo; Adalimumab

Eli Lilly and Company - Recruiting 18 years or older.
- A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis.
ixekizumab; Placebo; Adalimumab

Psoriasis Clinical Trial using Brodalumab

Amgen - Recruiting 18 years to 75 years.
- An Open-label Study to Evaluate the Effect of Brodalumab on the Pharmacokinetics of Midazolam and Assess Single-Dose Brodalumab Pharmacokinetics in Subjects With Moderate to Severe Plaque Psoriasis.
Brodalumab

Psoriasis Clinical Trial using Vehicle; M518101

Maruho North America Inc. - Recruiting 18 years or older.
- A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center PhaseIII Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis.
Vehicle; M518101

Psoriasis Clinical Trial using M518101

Maruho North America Inc. - Recruiting 18 years or older.
- An Open-label, Multi-center, Long-term Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis.
M518101

Psoriasis Clinical Trial using Etanercept

Pfizer - Recruiting 4 years to 17 years.
- Long-Term, Prospective, Observational Cohort Study of Safety and Effectiveness of Pediatric Psoriasis Patients Treated With Etanercept in a Naturalistic Setting: A Post-Authorization Safety Study (PASS).
Etanercept

Metabolic Disease, Cardiovascular Disease, or Inflammation Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Human Translational Studies of Inflammation and Cardiometabolic Diseases: The Psoriasis, Atherosclerosis and Cardiometabolic Disease (PACI) Initiative.

Psoriasis Clinical Trial

Janssen Pharmaceutica N.V., Belgium - Recruiting 18 years or older.
- EPidemiological Study In Patients With Recently DiagnosEd PSOriasis: Clinical Assessment and Psychosocial Impact of This Disease.

Psoriasis Clinical Trial using Skin biopsy; Blood test

Rockefeller University - Recruiting 18 years to 80 years.
- Comparative Analysis of Small and Large Plaque Psoriasis.
Skin biopsy; Blood test

Psoriasis Clinical Trial using VB-201 80mg; VB-201 160mg; Placebo

Vascular Biogenics Ltd. operating as VBL Therapeutics - Recruiting 18 years to 75 years.
- A Randomized, Double Blind, Dose Ranging, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis.
VB-201 80mg; VB-201 160mg; Placebo

Psoriasis, Cardiovascular Diseases, or Dyslipidemia Clinical Trial

George Washington University - Recruiting 18 years to 80 years.
- A Case Control Study to Evaluate Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis..

Psoriasis, or Nonalcoholic Fatty Liver Disease Clinical Trial

George Washington University - Recruiting 18 years to 80 years.
- A Case Control Study to Evaluate the Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) Among Patients With Psoriasis.

Plaque Psoriasis Clinical Trial using Ixekizumab Auto-Injector; Ixekizumab Prefilled Syringe

Eli Lilly and Company - Recruiting 18 years or older.
- Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis.
Ixekizumab Auto-Injector; Ixekizumab Prefilled Syringe

Psoriasis Clinical Trial using Topical steroids

University of Zurich - Recruiting 18 years or older.
- A Phase IV, Randomized, Double Blind, Placebo Controlled, Single-center Study of the Impact of Topical Steroids on Narrow Band UVB (Ultraviolet B) and Dithranol Combination Treatment of Psoriasis (DIPSO).
Topical steroids

Plaque Psoriasis Clinical Trial using Calcitriol 3 mcg/g ointment

Galderma - Recruiting 2 years to 12 years.
- Pharmacokinetics and Pharmacodynamics of Calcitriol 3 Mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis.
Calcitriol 3 mcg/g ointment

Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, or Hypert Clinical Trial using Etanercept

Massachusetts General Hospital - Recruiting 18 years or older.
- Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis.
Etanercept

Psoriasis, or Psoriasis Vulgaris Clinical Trial

Johann Wolfgang Goethe University Hospitals - Recruiting 18 years or older.
- Patient Orientated Basic Science Investigation: Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris.

Psoriasis Clinical Trial using blood test

National Taiwan University Hospital - Recruiting N/A or older.
- Effect of Atopic Diathesis as Assessed by Serum Th1/Th2 Cytokine Profile on Clinical Manifestation of Psoriasis.
blood test